Extraordinary and Ordinary General Shareholders' meeting and share capital decrease
29 Maggio 2020 - 6:00PM
Extraordinary and Ordinary General Shareholders' meeting and share
capital decrease
Minutes of the Extraordinary and Ordinary
General Shareholders’ Meeting of 26 May
2020
Capital decrease
The Extraordinary and Ordinary General Meeting
of Spineway’s shareholders that was held behind closed doors on 26
May 2020, at 2 p.m. at the Group’s registered office located at 7
allée Moulin Berger, 69130 Ecully, adopted all the resolutions
submitted by over 90% except for resolution no. 10, which was
dismissed unanimously at the Board of Directors’ recommendation.
During this Meeting, the decision was approved to decrease the
company’s share capital by absorbing losses and decreasing the par
value of the shares.
Prior to this decision, on 25 May 2020, the
Board of Directors recorded all the capital increases resulting
from the conversions of Convertible Bonds under the agreement for
the issue of bonds convertible into shares with attached warrants
entered into with Negma Group Ltd. Indeed, the share capital was
increased to €17 160 927.79, representing
1 716 092 779 ordinary shares with a face value of
€0.01 per share.
After the General Meeting amended the 12th
resolution to take into account the aforementioned capital
increase, as well as the previous capital increase reserved for
Negma Group Ltd. representing a notional amount of €4 565 217 (see
press release dated 20 May 2020), a technical capital decrease of
€12 012 649.45 was recorded, bringing the share capital
down from €17 160 927.79 to €5 148 278.34 by
decreasing the par value of the shares from €0.01 to €0.003, with
the number of shares remaining unchanged at
1 716 092 779 shares.
As per its strategy, Spineway will
continue its development and create – via targeted external growth
– a Group that will be a reference in Europe in the field of spinal
surgery.
SPINEWAY IS ELIGIBLE FOR THE PEA-PME
(EQUITY SAVINGS PLANS FOR SMES)
Upcoming: 2020 half-year revenue
– 9 July 2020
This press release has been prepared in both
English and French. In case of discrepancies, the French version
shall prevail.
Spineway
designs, manufactures and markets innovative implants and surgical
instruments for treating severe disorders of the spinal
column.
Spineway has
an international network of over 50 independent distributors and
90% of its revenue comes from exports.
Spineway,
which is eligible for investment through FCPIs (French unit trusts
specializing in innovation), has received the OSEO Excellence award
since 2011 and has won the Deloitte Fast 50 award (2011). Rhône
Alpes INPI Patent Innovation award (2013) – INPI Talent award
(2015).
ISIN:
FR0011398874 - ALSPW
Contacts:
SPINEWAY Shareholder-services line
Available Tuesday through Thursday (10 a.m. – 12 p.m.) +33 (0)811
045 555 |
Eligible PEA PMEALSPWEuronextGrowth |
AELIUM Finance et Communication Investor relations
Solène Kennis spineway@aelium.fr |
Grafico Azioni Spineway (EU:ALSPW)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Spineway (EU:ALSPW)
Storico
Da Apr 2023 a Apr 2024